NASDAQ: IOSP · Specialty Chemicals
Innospec (IOSP) fair value: undervalued or overvalued?
As of 26 Sep 2026, Faircurve's model values Innospec (IOSP) at $95.18 a share. The stock last closed at $97.41, which puts the model's fair value 2.3% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. Innospec Inc.
Faircurve Insights · 26 Sep 2026
Innospec Inc., founded in 1938 as Octel Corp. and rebranded in January 2006, is a global company headquartered in Englewood, Colorado. It focuses on the creation, production, formulation, promotion, and distribution of unique chemical products.
Faircurve's model on 26 Sep 2026 gave a fair value of $95.18 a share, the midpoint of 2,000 simulations. The previous run, on 19 Sep 2026, gave $90.52, so the fair value moved +5.1%. The calibrated range over 63 trading days is $79.85 to $116.05, built from the fair value, and ranges built this way held the price 60% of the time at this horizon over 4,327 past valuations. The evidence grade is High.
The overall quality score against comparable companies is 59 out of 100. The model compares it with WD-40 Company (WDFC), H.B. Fuller Company (FUL), Hawkins, Inc. (HWKN), Quaker Houghton (KWR), Minerals Technologies Inc. (MTX), and Ashland Inc. (ASH). Moves around the last 8 earnings reports include +7.6% on 4 Aug 2026 and +14.7% on 5 Nov 2024.
Written from the figures on this page for the 26 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give IOSP?
The calibrated range for IOSP over 63 trading days is $79.85 to $116.05. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $80.64 to $111.55. In 43% of the simulations the fair value came out above the price the model ran on.
How does IOSP score on business quality?
Innospec's overall quality score is 59 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 71 | 11.1%ROIC | 6.1% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 22 | 0.53xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 42 | -3.7%Revenue growth, trailing | -2.2% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 50 | 1.0%Net buybacks / market value | 2.3% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | -1.18xNet debt / EBITDA | 4.11x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 100 | 0.4 ptsEBITDA margin downside volatility, 5y | 3.0 pts |
How does IOSP compare with similar companies?
The companies in specialty chemicals closest to Innospec in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| NGVT Ingevity Corporation | $72.41 | $74.77 | +3.3% | Low evidence grade |
| WDFC WD-40 Company | $203.02 | $186.47 | -8.2% | Fairly valued |
| FUL H.B. Fuller Company | $50.20 | $60.19 | +19.9% | Undervalued |
| HWKN Hawkins, Inc. | $131.41 | $119.67 | -8.9% | Fairly valued |
| CC The Chemours Company | $13.71 | $13.52 | -1.4% | Low evidence grade |
| KWR Quaker Houghton | $160.73 | $133.78 | -16.8% | Overvalued |
| MTX Minerals Technologies Inc. | $66.43 | $70.34 | +5.9% | Fairly valued |
| ASH Ashland Inc. | $69.52 | $64.91 | -6.6% | Fairly valued |
When does IOSP report earnings, and how has the stock reacted?
Innospec's next earnings report is scheduled for 3 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 7.5% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How IOSP moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 4.6%.
| Report date | Two session move |
|---|---|
| 4 Aug 2026 | +7.6% |
| 7 May 2026 | +3.7% |
| 17 Feb 2026 | -0.3% |
| 4 Nov 2025 | +0.5% |
| 5 Aug 2025 | -1.4% |
| 8 May 2025 | -8.2% |
| 18 Feb 2025 | -5.5% |
| 5 Nov 2024 | +14.7% |
Innospec at a glance
Innospec Inc., founded in 1938 as Octel Corp. and rebranded in January 2006, is a global company headquartered in Englewood, Colorado. It focuses on the creation, production, formulation, promotion, and distribution of unique chemical products.
- Market value
- $2.4B
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Revenue expected, next twelve months
- $2.0B
- Consensus revenue growth, next fiscal year
- +7.1%
- Analysts with estimates
- 2
- Beta to the US market
- 0.45
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Innospec on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for IOSP was $90.52. As of 26 Sep 2026 it is $95.18, a change of +5.1%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Innospec's valuation
Is Innospec stock undervalued or overvalued?
On Faircurve's model, IOSP reads as Fairly valued as of 26 Sep 2026. The model's fair value is $95.18 a share against a last close of $97.41, a gap of -2.3%.
What is IOSP's fair value?
$95.18 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $80.64 to $111.55.
What price range does the model give IOSP?
$79.85 to $116.05 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Innospec report earnings next?
The next report is scheduled for 3 Nov 2026. Companies can move their dates.
How much has IOSP moved on past earnings reports?
Across its last 8 reports the median two session move was 4.6%, ignoring direction. The largest was +14.7% around the report of 5 Nov 2024.
How confident is the model in this valuation?
The model's evidence grade for IOSP is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.